晚期非小细胞肺癌的一线靶向及免疫治疗进展  

Advances in first-line targeting and immunotherapy for advanced non-small cell lung cancer

作　　者：董志兰 周丝吉 杨翠林 周开华[2] DONG Zhilan;ZHOU Siji;YANG Cuilin;ZHOU Kaihud(Ganmei Hospital Afiliated to Kunming Medical University,Kunming650000;Department of respiratory medicine,Ganmei Hospital,Kunming first people's Hospital,Kunming650000,China)

机构地区：[1]昆明医科大学附属甘美医院,650000 [2]昆明市第一人民医院甘美医院呼吸科,650000

出　　处：《中国老年保健医学》2022年第5期104-108,共5页Chinese Journal of Geriatric Care

摘　　要：肺癌的发病率及死亡率是全世界恶性肿瘤中最高的,其中又以非小细胞肺癌(NSCLC)多见,大多数患者是在晚期才被确诊,其预后不良、生存率低。近年来,针对NSCLC的药物治疗取得了重大进展,并明显提高了患者的生存率。本文归纳了晚期NSCLC常用的一线靶向及免疫治疗药物及研究进展,以期为个体化治疗提供指引,造福更多患者。The morbidity and mortality of lung cancer are the highest among malignant tumors in the world, and non-small cell lung cancer(NSCLC)is the most common.Most patients are diagnosed in the late stage, and their prognosis is poor and the survival rate is low.In recent years, drug treatment for NSCLC has made significant progress, and significantly improved the survival rate of patients.This article summarizes the commonly used first-line targeting and immunotherapeutic drugs and research progress in advanced NSCLC,and makes a summary and prospect, in order to provide guidance for individualized treatment for the benefit of more patients.

关 键 词：非小细胞肺癌 靶向治疗 免疫治疗 一线治疗 

分 类 号：R734.2[医药卫生—肿瘤]